Intra-tumoural manganese is associated with radioresistance and overall survival in glioblastoma
Abstract Background: Glioblastoma (GBM) is relatively radioresistant compared to other malignancies. Like other tumours undergoing radiotherapy, there is a variable response in similar patients having identical treatments. Methods: Our objective was to identify a predictive biomarker of radioresistance in GBM, that we contend will apply to all solid cancers. Results: This retrospective study includes a homogenous cohort of 13 GBM patients (9 males, 4 females), carefully selected to minimise the influence of many known prognostic factors. Histopathology slides were analysed using laser ablation - inductively coupled plasma - mass spectrometry (LA-ICP-MS), measuring intra-tumoural manganese (Mn), iron (Fe), copper (Cu) and zinc (Zn). [...]
Letter Re: Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study
No abstract available. Read Full Paper
Machine Learning Automates Reflectance Confocal Microscopy Imaging, Enabling Improved Scalability in Clinical Practice
No abstract available. Read Full Paper
Evaluation of Multiple Tissue Levels Frequently Upstages Patients With Clinically Localized Thin Primary Cutaneous Melanoma
Abstract Background: Breslow thickness (BT), ulceration, and microsatellitosis are critical prognostic parameters for cutaneous melanoma staging. These parameters can vary depending on the number of tissue levels examined from individual paraffin blocks. We sought to evaluate all prognostic histopathologic parameters in melanoma for their variations between levels, taken at regular intervals, in a single study. Methods: We analyzed 40 consecutive cases of primary cutaneous (nonacral) melanoma through five hematoxylin and eosin sections, taken at 100 μm intervals, for staging and prognostic parameters. Results: Examination of additional levels resulted in (a) an increase in BT in 47.5% (19 out of 40) of cases [...]
Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial
Abstract Background: PET/CT is widely used in the staging of patients with melanoma groin lymph node (LN) metastases. This study aims to utilise prospectively collected data to determine the accuracy of this modality in the diagnosis of pelvic metastases in those patients with known inguinal LN involvement. Methods: Data collected as part of the Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE-FM) trial was analysed. Patients with known inguinal LN metastases were evaluated with 18 F-FDG PET/CT. Those without evidence of pelvic LN abnormalities were randomised to inguinal dissection or ilio-inguinal dissection. Those with evidence of abnormality in the pelvic [...]
Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial
Abstract Importance: Mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) cancers constitute one of the most immunogenic tumors. Anti-programmed cell death 1 (PD-1) monotherapy provides durable responses in a third of patients with advanced dMMR/MSI-H noncolorectal cancers. Combined anti-PD-1/cytotoxic lymphocyte antigen 4 (CTLA-4) blockade using nivolumab and ipilimumab has shown superiority to anti-PD-1 monotherapy in other immunogenic cancers such as metastatic melanoma. The Combination Immunotherapy in Rare Cancers Under Investigation (MOST-CIRCUIT) is the first trial that investigated combined anti-PD-1/CTLA-4 blockade in advanced dMMR/MSI-H noncolorectal cancers. Objective: To evaluate the efficacy and safety of combined anti-PD-1/CTLA-4 blockade using nivolumab and ipilimumab in advanced dMMR/MSI-H noncolorectal [...]
The Prognostic Significance of Tumoral Melanosis
Abstract Background: Tumoral melanosis (TM) is a histological term to describe a nodular aggregation of macrophages containing melanin pigment (melanophages) that is devoid of viable melanocytes. It is most often identified in skin, where it may be appreciated clinically as a pigmented lesion; however, it can also be found in other organs such as lymph nodes. The presence of TM is usually thought to signify the presence of a regressed melanoma or other pigmented tumor. Until recently, it was a relatively uncommon finding; however, with the use of effective systemic therapies against melanoma, its occurrence in histological specimens is more [...]
Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH-Dx V2.0 and the WHO Skin5
Abstract In this Special Issue of the Journal of Cutaneous Pathology in memory of Dr. Martin C. Mihm, Jr, we highlight his many contributions over more than 50 years to the catalog of specific melanocytic tumor terminology. Dr. Mihm was an active participant in the International Melanoma Pathology Study Group (IMPSG). Discussions led to proposed recommendations for changes in the terminology of melanocytic tumors and their standardized diagnostic reporting. Histopathological reports of melanocytic tumors provide critical information that guides patient counseling and therapy. Importantly the pathology report must relay whether the melanocytic tumor is benign, intermediate, or malignant, and [...]
Melanoma 2.0: Time to Move Beyond Breslow Thickness?
No abstract available. Read Full Paper